ARR fever hits fintech: ‘We are still relevant’
THE SO WHAT
Fintechs chasing ARR optics are trying to re-rate themselves as SaaS just as SaaS multiples are compressing. If your revenue has balance-sheet risk, regulatory drag, or transaction volatility, assume investors will haircut any ‘ARR’ label and underwrite to cash and cohort quality instead.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureNSE Said to Seek Up to $55 Billion Valuation in Record India IPO
A $55B IPO for India’s NSE would crystallize how much value has accrued to market infrastructure in high-growth economies. If you operate in India’s capital markets, expect more scrutiny on fees, data products, and tech modernization once public investors are in the loop.
Startups & VentureAdaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
A $15M seed from an Adaptive Biotech co-founder to rethink how AI trains on scientific data points to a new stack layer: domain-native corpora and training regimes, not just bigger models. If you’re in life sciences, the defensible asset may be your curated experimental graph, not your in-house model weights.
AI proptech startup EliseAI is in talks to raise a new round of funding at a $3.7 billion valuation
A $3.7B valuation for EliseAI’s real estate assistants shows vertical AI is getting priced like core workflow software, not sidecar tools. If you operate in a data-rich, transaction-heavy vertical and don’t have a domain-specific assistant in market, assume your category will see similar capital and competitive pressure.
Startups & VentureWispr raised $280mn at $2bn to argue the text box is finished
$280mn into a speech-first interface that pipes cleaned-up text into any app is a bet that the cursor — not the app — is the new control point. If you build productivity software, assume voice-native workflows will sit on top of you and compete for user mindshare; optimize for being a great target, not the only interface.